Irene La-Beck Laboratory
About Us
information about lab
Research Interest
- Drug delivery
- Immunotherapy
- Cancer chemotherapy
The Team
 |
 |
|
Patricia Back Graduate Student/ Research Assistant |
Md Rakibul Islam Graduate Student/ Research Assistant |
- President's Early Career Investigator Award, TTUHSC, 2017
- New Investigator Award, American College of Clinical Pharmacy, 2016
- European Foundation for Clinical Nanomedicine Fellowship, European Foundation for Clinical Nanomedicine, 2014
- Focused Investigator Training Scholarship, American College of Clinical Pharmacy, 2014
- First place poster, TTUHSC SOP, 2011
- Anderson T, Wooster A, La-Beck I, Saha D, Lowe D. Antibody-drug conjugates: an evolving approach for melanoma treatment. Melanoma research. 2021;31(1):1-17.
- La-Beck I, Islam M, Markiewski M. Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine. Frontiers in immunology. 2021;11:603039.
- La-Beck I, Liu X, Shmeeda H, Shudde C, Gabizon AA. Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment. Seminars in cancer biology. 2021;68:175-185.
- La-Beck I, Nguyen DT, Le AD, Alzghari SK, Trinh ST. Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer. Pharmacotherapy. 2020;40(3):239-255.
- Gabizon AA, de Rosales RTM , La-Beck I. Translational considerations in nanomedicine: The oncology perspective. Advanced drug delivery reviews. 2020;158:140-157.
- Trinh S, Le A, Gowani S, La-Beck I. Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines. Asia-Pacific journal of oncology nursing. 2019;6(2):154-160.
- La-Beck I, Liu X, Wood L. Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug Delivery. Frontiers in pharmacology. 2019;10:220.
- Rajan R, Sabnani MK, Mavinkurve V, Shmeeda H, Mansouri H, Bonkoungou S, Le AD, Wood L, Gabizon AA, La-Beck I. Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate. Journal of controlled release : official journal of the Controlled Release Society. 2018;271:139-148.
- La-Beck I, Gabizon AA. Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy. Frontiers in immunology. 2017;8:416.
- Le AD, Alzghari SK, Jean G, La-Beck I. Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. Therapeutics and clinical risk management. 2017;13:223-236.
- Walko CM, Aubert RE, La-Beck I, Clore G, Herrera V, Kourlas H, Epstein RS, McLeod HL. Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib. The oncologist. 2017;22(2):208-212.
- Anchordoquy TJ, Barenholz Y, Boraschi D, Chorny M, Decuzzi P, Dobrovolskaia MA, Farhangrazi
ZS, Farrell D, Gabizon A, Ghandehari H, Godin B, La-Beck I, Ljubimova J, Moghimi SM,
Pagliaro L, Park JH, Peer D, Ruoslahti E, Serkova NJ, Simberg D. Mechanisms and Barriers
in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions. ACS nano. 2017;11(1):12-18.
Gabizon AA, Patil Y, La-Beck I. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2016;29:90-106. - Petersen GH, Alzghari SK, Chee W, Sankari SS, La-Beck I. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. Journal of controlled release : official journal of the Controlled Release Society. 2016;232:255-64.
- La-Beck I, Jean G, Huynh C, Alzghari SK, Lowe D. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. Pharmacotherapy. 2015;35(10):963-76.
- Golan T, Grenader T, Ohana P, Amitay Y, Shmeeda H, La-Beck I, Tahover E, Berger R, Gabizon AA. Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. Cancer medicine. 2015;4(10):1472-83.
- Rajan R, Karbowniczek M, Pugsley HR, Sabnani MK, Astrinidis A, La-Beck I. Quantifying autophagosomes and autolysosomes in cells using imaging flow cytometry. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2015;87(5):451-8.
- Sabnani MK, Rajan R, Rowland B, Mavinkurve V, Wood L, Gabizon AA, La-Beck I. Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses. Nanomedicine : nanotechnology, biology, and medicine. 2015;11(2):259-62.
- Caron WP, Lay JC, Fong AM, La-Beck I, Kumar P, Newman SE, Zhou H, Monaco JH, Clarke-Pearson DL, Brewster WR, Van Le L, Bae-Jump VL, Gehrig PA, Zamboni WC. Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology. The Journal of pharmacology and experimental therapeutics. 2013;347(3):599-606.
- Gibson JM, Alzghari S, Ahn C, Trantham H, La-Beck I. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. The oncologist. 2013;18(9):1022-31.
- La-Beck I, Zamboni BA, Gabizon A, Schmeeda H, Amantea M, Gehrig PA, Zamboni WC. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer chemotherapy and pharmacology. 2012;69(1):43-50.
- Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck I, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clinical pharmacology and therapeutics. 2010;87(6):735-42.
- La-Beck I, European Summit for Clinical Nanomedicine and Targeted Medicine, European
Foundation for Nanomedicine, Basel, Switzerland June 2015.
Liposomes: a double edged sword in cancer? - La-Beck I, European Society for Medical Oncology (ESMO) Annual Conference, European
Society for Medical Oncology, Spain 2014.
A phase I study of mitomycin-c prodrug in pegylated liposomes. - La-Beck I, European Summit for Clinical Nanomedicine and Targeted Medicine, European
Foundation for Nanomedicine, Basel, Switzerland 2014.
Effects of pegylated liposomes on functionality of macrophages and lymphocytes in tumors - La-Beck I, Society of Toxicology (SOT) Annual Conference, Society of Toxicology, Pheonix,
AZ 2014.
Impact of liposome-induced complement activation on tumor growth and angiogenesis - La-Beck I, Keystone Symposium on Autophagy, Immunity, and Inflammation, Keystone Symposium,
Montreal, Canada 2013.
Monitoring Autophagy Modulation by Nanoparticles Using Multispectral Imaging - La-Beck I, Cancer Nanotechnology, Gordon Research Conference, Waterville, ME July
2011.
Complement Activation As Biomarkers for Toxicity and Response to Anticancer Nanoparticles. - La-Beck I, ASCO 2011, ASCO, Chiacgo, IL June 2011.
Cellular Function of the Mononuclear Phagocyte System (MPS) as a Phenotypic Probe For Pegylated Liposomal Doxorubicin Pharmacokinetic in Patients with Recurrent Ovarian Cancer - La-Beck I, ASCO 2011, ASCO, Chicago, IL June 2011.
Technetium-99m sulfur colloid as a phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in patients with recurrent epithelial ovarian cancer. - La-Beck I, AACR 2012, AACR, Chicago, IL April 2011.
Effects of bortezomib on the pharmacokinetics of pegylated liposomal doxorubicin
Contact Us:
Irene La-Beck, Pharm.D.
Associate Professor
Department of Immunotherapeutics & Biotechnology
Office#: (325) 696-0433
Office: Room 2516
Texas Tech University Health Sciences Center
School of Pharmacy
1718 Pine Street
Abilene, TX, USA, 79601
Funding: